Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr., Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
2.

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A.

Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.

3.

Mechanisms regulating T-cell infiltration and activity in solid tumors.

Lanitis E, Dangaj D, Irving M, Coukos G.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii18-xii32. doi: 10.1093/annonc/mdx238.

PMID:
29045511
4.

Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.

Zsiros E, Dangaj D, June CH, Kandalaft LE, Coukos G.

Oncoimmunology. 2015 Oct 19;5(5):e1062210. doi: 10.1080/2162402X.2015.1062210. eCollection 2016 May.

5.

Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Smith JB, Lanitis E, Dangaj D, Buza E, Poussin M, Stashwick C, Scholler N, Powell DJ Jr.

Mol Ther. 2016 Nov;24(11):1987-1999. doi: 10.1038/mt.2016.149. Epub 2016 Jul 21.

6.

Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.

Karapetsas A, Giannakakis A, Dangaj D, Lanitis E, Kynigopoulos S, Lambropoulou M, Tanyi JL, Galanis A, Kakolyris S, Trypsianis G, Coukos G, Sandaltzopoulos R.

Biomed Res Int. 2015;2015:712438. doi: 10.1155/2015/712438. Epub 2015 Sep 13.

7.

Isolation and Validation of Anti-B7-H4 scFvs from an Ovarian Cancer scFv Yeast-Display Library.

Dangaj D, Scholler N.

Methods Mol Biol. 2015;1319:37-49. doi: 10.1007/978-1-4939-2748-7_2.

PMID:
26060068
8.

The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G.

Clin Cancer Res. 2015 Jun 15;21(12):2840-50. doi: 10.1158/1078-0432.CCR-14-2777. Epub 2015 Feb 23.

9.

A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.

Lanitis E, Smith JB, Dangaj D, Flingai S, Poussin M, Xu S, Czerniecki BJ, Li YF, Robbins PF, Powell DJ Jr.

Hum Gene Ther. 2014 Aug;25(8):730-9. doi: 10.1089/hum.2014.006.

10.

Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer.

Giannakakis A, Karapetsas A, Dangaj D, Lanitis E, Tanyi J, Coukos G, Sandaltzopoulos R.

Int J Biochem Cell Biol. 2014 Aug;53:389-98. doi: 10.1016/j.biocel.2014.05.031. Epub 2014 May 29.

PMID:
24880093
11.

Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses.

Dangaj D, Scholler N.

Oncoimmunology. 2013 Aug 1;2(8):e25913. Epub 2013 Jul 31.

12.

Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.

Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R, Ra HJ, Danet-Desnoyers G, Powell DJ Jr, Scholler N.

Cancer Res. 2013 Aug 1;73(15):4820-9. doi: 10.1158/0008-5472.CAN-12-3457. Epub 2013 May 30.

13.

Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.

Lanitis E, Dangaj D, Hagemann IS, Song DG, Best A, Sandaltzopoulos R, Coukos G, Powell DJ Jr.

PLoS One. 2012;7(11):e49829. doi: 10.1371/journal.pone.0049829. Epub 2012 Nov 26.

14.

Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody.

Dangaj D, Abbott KL, Mookerjee A, Zhao A, Kirby PS, Sandaltzopoulos R, Powell DJ Jr, Lamazière A, Siegel DL, Wolf C, Scholler N.

PLoS One. 2011;6(12):e28386. doi: 10.1371/journal.pone.0028386. Epub 2011 Dec 6.

15.

Reactive oxygen species and HIF-1 signalling in cancer.

Galanis A, Pappa A, Giannakakis A, Lanitis E, Dangaj D, Sandaltzopoulos R.

Cancer Lett. 2008 Jul 18;266(1):12-20. doi: 10.1016/j.canlet.2008.02.028. Epub 2008 Apr 18. Review.

PMID:
18378391

Supplemental Content

Loading ...
Support Center